Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 27, 2016

Primary Completion Date

August 10, 2017

Study Completion Date

May 26, 2018

Conditions
Hypercholesterolemia
Interventions
BIOLOGICAL

Evolocumab

Administered by subcutaneous injection

DRUG

Ezetimibe

Tablet for oral administration

DRUG

Placebo to Evolocumab

Administered by subcutaneous injection

DRUG

Placebo Ezetimibe

Tablet for oral administration

Trial Locations (35)

466-8560

Research Site, Nagoya

466-8650

Research Site, Nagoya

260-8677

Research Site, Chiba

292-8535

Research Site, Kisarazu-shi

271-0077

Research Site, Matsudo-shi

818-8516

Research Site, Chikushino-shi

811-3195

Research Site, Koga-shi

962-0001

Research Site, Sukagawa-shi

962-8503

Research Site, Sukagawa-shi

734-8551

Research Site, Hiroshima

650-0017

Research Site, Kobe

306-0041

Research Site, Koga-shi

920-0293

Research Site, Kahoku-gun

920-8650

Research Site, Kanazawa

923-8560

Research Site, Komatsu-shi

020-0866

Research Site, Morioka

020-8505

Research Site, Morioka

890-8520

Research Site, Kagoshima

245-8575

Research Site, Yokohama

860-8556

Research Site, Kumamoto

862-0976

Research Site, Kumamoto

606-8507

Research Site, Kyoto

989-6143

Research Site, Ohsaki-shi

901-2393

Research Site, Nakagami-gun

530-0001

Research Site, Osaka

553-0003

Research Site, Osaka

354-0031

Research Site, Fujimi-shi

350-0495

Research Site, Iruma-gun

332-0012

Research Site, Kawaguchi-shi

430-0929

Research Site, Hamamatsu

113-8655

Research Site, Bunkyo-ku

103-0027

Research Site, Chuo-ku

207-0014

Research Site, Higashiyamato-shi

180-0022

Research Site, Musashino-shi

142-8666

Research Site, Shinagawa-ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY